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Abstract 
 
Objective 
 
PRECIS - 2 is a tool that could improve design insight for trialists. Our 
aim was to validate the PRECIS - 2 tool, unlike its predecessor, testing 
the discriminant validity and inter-rater reliability. 
 
Study design and Setting 
 
Over 80 international trialists, methodologists, clinicians and 
policymakers created PRECIS - 2 helping to ensure face and content 
validity. The inter-rater reliability of PREC IS - 2 was measured using 19 
experienced trialists who used PRECIS - 2 to score a diverse sample of 
15 RCT protocols. Discriminant validity was tested with two raters to 
independently determine if the trial protocols were more pragmatic or 
more explanatory, with scores from the 19 raters for the 15 trials as 
predictors of pragmatism. 
 
Results 
Inter-rater reliability was generally good, with seven out of nine domains 
having an ICC over 0.65. Flexibility (Adherence) and Recruitment had 
wide confidence intervals but raters found these difficult to rate and 
wanted more information. Each of the nine PRECIS - 2 domains could 
be used to differentiate between trials taking more pragmatic or more 
explanatory approaches with better than chance discrimination for all 
domains. 
 
Conclusion 
 
We have assessed the validity and reliability of PRECIS - 2. An 
elaboration paper and website provide guidance to help future users of 
the tool which is continuing to be tested by trial teams, systematic 
reviewers and funders. 
 
Six key words: 
 
Randomized controlled trials; Clinical trial methodology; Validity and 
reliability; Face validity Pragmatic clinical trial; Trial design. 
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i
The PRECIS-2 tool has good inter-rater reliability and modest discriminant 
validity 
 
What’s new? 
• The original PRECIS tool did not have its validity and reliability formally measured. 
• The inter-rater reliability of PRECIS-2 was measured using 19 raters (trialists from seven 
countries) to score a varied sample of 15 RCT protocols.   
• Inter-rater reliability was generally good, with seven of nine domains having an Intraclass 
Correlation Coefficient over 0.65.  
• Each of the nine PRECIS-2 domains could be used to differentiate between trials taking more 
pragmatic or more explanatory approaches with better than chance discrimination for all 
domains.  
• The validity and reliability of PRECIS-2 has been assessed. 
 
Introduction 
 
The aim of the original PRECIS (PRagmatic Explanatory Continuum Indicator Summary) tool [1,2], and 
of the current PRECIS-2 tool [3] is to enable trialists to match their design decisions to the intended 
purpose of the trial.  Some trials are conducted to understand how an intervention works 
(explanatory or efficacy trials), whereas others are intended to inform clinical and service delivery 
decisions in usual healthcare settings in the real world (pragmatic or effectiveness trials) [1,2,3]. 
Although the original PRECIS tool (2009) [1,2] was increasingly cited it was criticised for the lack of 
inter-rater variability assessments and the absence of a rating scale for each domain [4,5,6,7,8].  
Users also wanted further explanation on the PRECIS domains to use the tool effectively. The 
PRECIS-2 tool [3] published in 2015, aimed to address these demands. It was the result of 
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collaboration with over 80 international trialists, clinicians and policymakers from 2011 to 2014 
involving a 2-round electronic Delphi, brainstorming meetings in Dundee, UK and Toronto, Canada 
and user testing of the PRECIS-2 tool with 19 individual trialists ranging from early career to 
experienced researchers [3,9,10]. This PRECIS-2 tool, like the original, was intended to be used 
prospectively, at the trial design stage, by a multi-disciplinary team to prompt discussion of each 
design choice, and thus ensure that the resulting trial design would match the intended question, 
whether it be pragmatic or explanatory.  
The nine domains in PRECIS-2: Eligibility, Recruitment, Setting, Organisation, Flexibility (delivery) and 
Flexibility (adherence), Follow up, Primary outcome and Primary analysis are each scored repeatedly 
as the trial protocol is developed, using a scale from “1” (very explanatory) to “5” (very pragmatic). A 
score of “1” indicates a highly explanatory design choice for that domain, suggesting that trial 
domain is intending to test an intervention under idealized, tightly controlled conditions, whereas a 
“5” would suggest that domain is intending to be very pragmatic and test the intervention under 
conditions close to routine clinical care. With all nine domains scored, trialists get a visual 
representation of their trial’s design on a wheel (Figure 1) – and can instantly see across all domains, 
whether the trial is more pragmatic (mostly near the rim of the wheel)  or more  explanatory (close 
to the hub or centre of the wheel).  
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Figure 1 The PRECIS-2 wheel (reprinted with permission from [3]). 
 
The validity and reliability of the original PRECIS tool (2009) was not formally measured [1,2]. Rather 
it was presented as a concept and readers were encouraged to try it out and further develop PRECIS. 
Some users did just this, using the original PRECIS tool [2] as it was intended prospectively at the trial 
design stage, for retrospective assessment in systematic reviews or to assess trials that were past 
the trial design stage and underway. Many had problems with inter-rater variability when multiple 
raters scored PRECIS domains for a trial.  For example, in a systematic review Koppenhaal et al 
tested a modified PRECIS tool and recommended using two raters to reduce subjectivity across all 
domains when assessing 20 trials using two raters [4]; Riddle et al found discussion helped his team 
of seven raters when they used the PRECIS tool as intended to design a trial; variation in PRECIS-2 
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scores pre-discussion for each individual were 1.16 for the average Standard Deviation becoming 
0.61 post discussion across all domains [5].  Witt in a systematic review of ten trials,  had low inter-
rater reliability amongst five raters using PRECIS after the first round of scoring but after a consensus 
meeting this improved and there was usually only one point difference (on a 5-point scale) for all 
domains [6].  Glasgow et al [7] assessed three studies with PRECIS using nine raters and found 
Intraclass Correlation Coefficient for domains was 0.72. While Sanchez et al assessed 113 trials using 
two raters, calculated weighted agreement scores for PRECIS ranged from 63.9 to 78.5 %, with a 
median of 73.9% [8]. All of these studies have been small, with few raters and/or trials being rated; 
the most raters used was seven but Riddle et al scored only one trial (their own) [5].  This work 
highlights that there were issues around inter-rater variability which we were keen to address in 
formally testing the validity and reliability of the PRECIS-2 tool. 
 
For PRECIS-2, we achieved face validity by consulting a large number of participants and potential 
users of the tool in creating and developing the updated tool. The modified tool, PRECIS-2, kept the 
simple format but addressed weaknesses through a scoring system, domains changes and additional 
guidance. We felt, however, that it would be useful to assess the reliability and other aspects of 
validity of the new tool at the point it was developed, so that its strengths and limitations would be 
known early in its life.  Moreover, having a validated tool might encourage more trialists to consider 
using the tool with their own trials.  Within the timeframe of KL’s PhD, it was not practical to 
prospectively quantitatively assess the use the PRECIS-2 tool by trial teams at the design stage of 
their trials (though some largely qualitative work was done [10].  To give an indication of validity and 
reliability we therefore decided to use the tool retrospectively on trials that had already been 
published, recognising that this would be a harder test for PRECIS-2 i.e. to be used by raters 
unfamiliar with the trials they were assessing and without discussion between raters.  It would, in 
other words, provide a conservative estimate of validity and reliability.   
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The aim of the work described here is to validate the PRECIS-2 tool. To ensure PRECIS-2 could be 
used to design different trials by different raters on a spectrum of pragmatism, from very 
explanatory to very pragmatic, we tested the face validity, inter-rater reliability and discriminant 
validity (ability of the domains to determine pragmatism) of PRECIS-2. We believed that it was 
important that the participants reflect trialists who are experienced and could be future users of the 
PRECIS-2 tool. It was also important that the sample of trial protocols that they assessed was varied 
to allow the tool to be used for all trial protocol designs.  
Methods 
Firstly (1) we undertook a sample size calculation using the Intra-class coefficient, then (2) we 
selected the trials that would be used to test out PRECIS-2. This was followed by (3) pilot testing the 
materials and methods to make it as easy as possible for individual participants to assist with validity 
and reliability testing. (4) A purposive sample of trialists were then invited to participate. In this 
project. (5) The inter-rater variability of the nine PRECIS-2 domains was then analysed. Finally (6) 
statistical analysis indicated the discriminant validity of PRECIS-2 to determine pragmatism.  
1. Sample size  
The key requirement for assessing the reliability of PRECIS-2 was to ensure we had sufficient raters 
involved in testing the PRECIS-2 tool. The Intraclass Correlation Coefficient, ICC acts as a measure of 
inter-rater reliability (see 5. Statistical analysis).  We were expecting an ICC near 0.7; Land and Koch 
view the range of 0.61 to 0.80 as “substantial agreement”. Assuming the ICC was in the region of 0.7, 
then 15 raters looking at 10, 15 or 20 trials would give precisions of +/- 0.20, +/- 0.17 and +/- 0.14, 
respectively. We aimed to give our 15 raters between 10 and 15 trials to rate.  
2. Selection of the trials for assessment  
We needed a broad spectrum of trials for raters to independently rate using the PRECIS-2 tool. We 
decided to use trial protocols because they give more detailed information on trial design than the 
final trial publications. We were given permission to access a database of trial protocol examples 
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assembled from public websites, journals, trial investigators, and industry sponsors by An-Wen Chan 
and Jennifer M Tetzlaff for SPIRIT – Standard Protocol Items: Recommendations for Interventional 
Trials [11].  The SPIRIT guidance for protocol reporting was published in 2013 (http://www.equator-
network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-
clinical-trials/) in response to poor reporting. 
 
ST and KL independently screened the 150 SPIRIT protocols, excluding all trial protocols longer than 
60 pages (approximately 10%) to reduce the burden on raters, who would have to read them. KL and 
ST each selected 20% of the SPIRIT database of trial protocols to include the different types of trials 
in terms of interventions (drug trials, therapy or educational programmes), settings (primary care, 
hospital and community), a range of countries, publications in different journals and, including 
cluster randomised and factorial designs. They agreed through discussion on a final selection of 15 
trial protocols (Supp 1), published between 2008 and 2011.  
 
3. Internal testing of the materials and procedure to guide future use 
KL developed the training materials and procedures for reviewers on how to use PRECIS-2, the nine 
PRECIS-2 domains and descriptions and the scoring system, with examples of trials rated by PRECIS-
2. These were pilot tested with four members of the PRECIS-2 development steering group and one 
independent primary care trialist (ST, FS, MZ, IG and KL) for clarity and ease of use.  
The pilot testers used these materials to assess three contrasting trials, purposively selected to test 
the PRECIS-2 tool: a single centre factorial trial in the USA -the physiotherapy versus corticosteroid 
trial [12]; a behavioural change cluster randomised trial in India using Accredited Social Health 
Activists (ASHA) to improve maternal and neonatal health [13] and a multi-centre trial in North of 
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England and Scotland comparing surgical intervention with conventional medical treatment in 
children with recurrent sore throat (NESSTAC) trial [14] (Supp. 1).   
 
Our test led to two changes. Firstly, to speed up the PRECIS-2 learning process for raters we 
produced a much shorter 3 page information sheet. Secondly, we reduced the number of PRECIS-2 
tool domains from ten to nine and removed “Organisation – comparison”. As the intention of the 
tool is primarily to help design trials which are useful for decision-making in usual care, our approach 
to PRECIS-2 was to simplify it by always drawing the comparison with existing patterns of usual care 
or standard of care.  
4. Selection and invitation of participants  
Thirty five personalised invitations (Figure 2) were sent on September 24th, 2013, to six different 
groups of potential raters, including: researchers who had been involved in an early stage of PRECIS-
2 development (a Delphi); early user-testers who had given feedback on initial versions of PRECIS-2; 
individuals who had participated in brainstorming meetings; methodologists in the Cochrane 
Methodology Review Group, the CONSORT group, the Scottish Clinical Trials Units and the EU-
funded DECIDE (Developing and Evaluating Communication Strategies to Support Informed Decisions 
and Practice based on Evidence) group; researchers who had worked with the original PRECIS tool; 
and editors of medical/trial journals.  Sampling was purposive: for this retrospective assessment of 
trial protocols using PRECIS-2 we wanted experienced trialists and methodologists who would be 
able to commit the not inconsiderable time required to do the assessments.   
Nineteen researchers agreed to take part, and were sent a concise PRECIS-2 training package 
comprising a 3-page explanation sheet, a PRECIS-2 wheel and table that could be used for scoring 
trial protocols.  Raters were sent 5 to 15 protocols each, in batches of five, with a new batch sent on 
receipt of the returned previous batch; the number of protocols depended on rater preference.  As 
this was a significant burden on time, raters were initially offered £100 as a notional payment for 
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about four hours work but as many raters waived payment, this enabled us to increase the financial 
incentive to £200 to complete the assessment of 15 trial protocols using PRECIS-2.  
 
5. Statistical analysis of the inter-rater reliability of the nine PRECIS-2 domains 
The Intraclass correlation coefficient (ICC) is a relatively simple statistical measure to assess variation 
and determine if raters were reaching similar decisions with regard to domain scores.  As there were 
two variables that could affect the rating, the raters and the trial protocols, we chose the two-way 
random effects model where both people (PRECIS-2 raters) and measures effects (trial protocols for 
scoring) are treated as random variables i.e. as a random sample of all potential raters and trial 
protocols. To determine the effect of missing data we undertook sensitivity analysis, imputing 
missing data in two ways: 1) using a score of “3” - equally pragmatic/explanatory and 2) undertaking 
multiple sensitivity analysis (10 imputations) in which randomly-generated values of “1” to “5” were 
inserted if there were missing values.  
6. Statistical analysis of the discriminant validity of PRECIS-2 to determine pragmatism 
While interrater reliability determines the reliability of the tool in different hands, discriminant 
validity examines the ability of the tool itself to discriminate between pragmatic and explanatory 
trials.  We were keen to evaluate discriminant validity by testing whether PRECIS-2 could accurately 
discriminate trials of varying degree of pragmatism (an ordinal variable) but discriminant validity is a 
binary concept, and requires a gold standard against which the performance of the instrument is 
compared.   
Ideally, to asses discriminant validity we would have asked participants to give subjective global 
ratings of pragmatism of the trial after reading the trial protocol, then participants would use 
PRECIS-2 to rate  the nine domains of PRECIS-2. However due to the already significant burden on 
raters this was not possible. Therefore we decided to determine discriminant validity to compare our 
own (ST, KL) subjective global (more pragmatic vs. more explanatory) ratings of each of the 15 trial 
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protocols. Two raters (KL, ST) independently used binary scores of more pragmatic = “1”, more 
explanatory =”0” to rate the overall pragmatism for the 15 trials. This was done by making a 
judgement of degree of pragmatism based on reading the trial publication, with KL and ST then 
reaching consensus through discussion. We used this as an implicit gold standard to compare with 
the median score of each domain of PRECIS 2), determined by as many as 18 raters, analysed using 
binary logistic regression, calculating Area under the curve (AUROC) odds (discriminant validity) - 
(Receiver Operating Characteristic Curve) (ROC Curve function) [10]. We used a Hosmer-Lemeshow 
goodness-of-fit statistic to assess calibration of the model. We saved the predicted probabilities for 
each domain and then using the ROC Curve function (Receiver Operating Characteristic Curve) 
calculated AUROC – Area under the curve.  This showed us the sensitivity/specificity of the different 
PRECIS-2 domain variables for different cut-offs. So, using the test variable as the predicted 
probability (PRE_1, PRE_2 etc.) and the State variables as Pragmatism (more pragmatic, more 
explanatory) we calculated how good each domain in the PRECIS-2 tool is at predicting whether the 
trial was more, or less pragmatic (using our subjective, consensus based gold standard) (1) displaying 
a ROC curve with diagonal reference line and Standard error and confidence interval. SPSS (version 
15.5) was used for this analysis. 
Results 
Participants 
After 10 weeks we had received a response from 91% (32/35), with 54% (19/35) of ratings returned. 
The 19 raters came from seven countries – USA (8), UK (3), Canada (3), The Netherlands (2), 
Argentina (1), Australia (1), and Germany (1). Of these, seven of the raters scored 15, and 12 scored 
10 trials (Supp 2). Six out of nineteen of the raters had assisted with the Delphi round, brainstorming 
or user testing and four of the nineteen raters had assisted with methodological testing of the 
original PRECIS tool. The remaining nine raters had not previously been involved in development of 
PRECIS or PRECIS-2.  
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Figure 2 Flow diagram of participants in validity and reliability testing 
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Results of the statistical analysis of the inter-rater reliability of the nine PRECIS-2 
domains 
For seven out of nine domains inter-rater reliability was good or modest with ICC over 0.65 and tight 
confidence intervals. Two domains Flexibility - adherence - ICC 0.57 and Recruitment - ICC 0.60 has 
lower inter-rater reliability with wide confidence intervals. These results are based on the best 
estimate of the ICC and confidence intervals for 10 trials and 12 raters as this was closest to our 
sample size calculations (Table1 and 2). To assess the effect of missing data we imputed values of 
“3” as equally pragmatic/explanatory to indicate the uncertainty in scoring (Table 1). We also 
randomly imputed values of “1” to “5” (Table 2). In Table 1 we looked at the ICC for five trials scored 
by 18 raters, 10 trials scored by 12 raters and 15 trials scored by seven raters, generally there was 
not much difference for the ICC for the different batches of trials. The ICC scores for the different 
domains in Table 1 with imputed values of “3” compared well to the ICC scores for the PRECIS-2 
domains in Table 2 for a complete set of 15 trials scored by 19 raters which included random values 
“1” to “5” for missing data (up to 38%).  
 
Table 1 Overall results for Inter-rater reliability for 9 PRECIS-2 domains including 
sensitivity analysis  
Domain Number 
of trials, 
raters  
No. Imputed 
values 
= 3 
1
 (%) 
Intraclass 
Correlation 
95% Confidence Interval 
    
Lower 
Bound 
Upper 
Bound 
Eligibility 15, 7 1 (0.74) 0.88*** 0.75 0.95 
 
10, 12 2 (1.67) 0.89*** 0.76 0.97 
 
5, 18 4 (4.4) 0.94*** 0.81 0.99 
Recruitment 15, 7 1 (0.74) 0.59** 0.18 0.84 
 
10, 12 2 (1.67) 0.60* 0.10 0.88 
 
5, 18 4 (4.4) 0.83*** 0.50 0.98 
Setting 15, 7 1 (0.95) 0.80*** 0.60 0.92 
 
10, 12 2 (1.67) 0.80*** 0.56 0.94 
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Domain Number 
of trials, 
raters  
No. Imputed 
values 
= 3 
1
 (%) 
Intraclass 
Correlation 
95% Confidence Interval 
 
5, 18 5 (4.4) 0.92*** 0.76 0.99 
Organisation 15, 7 2 (1.99) 0.72*** 0.44 0.89 
 
10, 12 9 (7.5) 0.83*** 0.61 0.95 
 
5, 18 6 (5.55) 0.75** 0.25 0.97 
Flex  Delivery 15, 7 3 (3.33) 0.74*** 0.47 0.90 
 
10, 12 6 (6.67) 0.85*** 0.67 0.96 
 
5, 18 6 (6.67) 0.92*** 0.75 0.99 
Flex Adherence 15, 5 0 0.50* -0.06 0.81 
 
15, 7 8 (7.62) 0.24ns -0.54 0.70 
 
10, 12 17 (15.74) 0.57* 0.04 0.88 
 
5, 18 18 (15.56) 0.72** 0.16 0.97 
Follow-up 15, 7 1 (1.11) 0.60** 0.18 0.84 
 
10, 12 8 (8.89) 0.80*** 0.55 0.94 
 
5, 18 6 (6.67) 0.85*** 0.55 0.98 
Primary outcome 15, 7 0 0.44ns -0.13 0.78 
 
10, 12 1 (1.11) 0.66** 0.24 0.900 
 
5, 18 3 (3.33) 0.84*** 0.54 0.98 
Primary analysis 15, 7 0 0.67*** 0.32 0.87 
 
10, 12 3 (3.33) 0.73*** 0.39 0.92 
 
5, 18 5 (5.55) 0.83*** 0.50 0.98 
 
†
 PRECIS-2 score = 3 equally pragmatic/explanatory chosen as score to indicate uncertainty in scoring. 
‡ 
Trials were scored in batches of 5, there were overall 19 raters but one rater asked for 10 trials but only 
scored the 2
nd
 batch of trials so did not score the 1
st
 five trials that 18 other raters scored.  
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Table 2 Rater scoring using randomly generated values (1 to 5) to impute missing data for 
PRECIS-2 domains using responses for 15 trials by 19 raters 
Domain % missing 
data* 
Intraclass 
Correlation 
95% Confidence Interval  
Significance 
   Lower 
Bound 
Upper 
Bound 
 
Eligibility 33 0.84 0.69 0.94 *** 
Recruitment 33 0.58 0.20 0.84 ** 
Setting 34 0.79 0.60 0.92 *** 
Organisation 36 0.72 0.46 0.89 *** 
Flex deliv. prov. 35 0.80 0.62 0.92 *** 
Flex adherence 38 0.54 0.12 0.82 * 
Follow-up 34 0.71 0.44 0.88 *** 
Primary Outcome 34 0.68 0.38 0.87 *** 
Primary Analysis  34 0.67 0.37 0.84 *** 
 
*approx. 93% of missing data is due to trials not being scored at all by raters  
 
Discriminant validity results 
Agreement between ST and KL on their implicit gold standard was 80% (12/15) pre-discussion, 
Cohen’s kappa 0.59 indicating moderate agreement. The three trials where there was disagreement 
in assigning a trial as being pragmatic or explanatory i.e. “1” instead of “0” were resolved following 
discussion.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 14 of 19 
 
The AUROC values for determining whether a trial is more pragmatic or more explanatory for the 
nine PRECIS-2 domains are displayed in Table 3, these are a numerical summary of the ROC curves 
(Supp 3).  These values have been placed in order of discriminative ability. A score of 1 would be the 
ideal score and indicate that a PRECIS-2 domain was perfect at discriminating between more 
pragmatic and more explanatory trials. Random performance, with no discriminant ability beyond 
chance would be 0.5. For the ROC curves ideally we would want the whole curve to be above the 
diagonal line. The results for all PRECIS-2 domains are greater than 0.5 although some are not 
significantly different from chance. Primary outcome is the single variable that is most likely to 
discriminate how pragmatic a trial is based on this data – AUROC 0.75. Then in order of 
discriminating between a more pragmatic and more explanatory approach: Follow-up 0.73, Primary 
analysis 0.72, Flexibility (delivery) 0.71, Eligibility 0.62, Recruitment 0.62, Flexibility adherence 0.60, 
Setting 0.59, Organisation 0.57.  
Table 3 Discriminant validity measured using Area Under the ROC curves (AUROC) 
Domains AUROC  95% Confidence intervals 
Primary Outcome 0.75 0.49-1.00 
Follow-up 0.73 0.48-0.99 
Primary analysis 0.72 0.45-1.00 
Flexibility delivery 0.71 0.44-0.99 
Eligibility 0.62 0.33-0.92 
Recruitment 0.62 0.32-0.92 
Flexibility adherence 0.60 0.30-0.89 
Setting 0.59 0.26-0.92 
Organisation 0.57 0.27-0.87 
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Discussion 
Our reliability and validity work found that PRECIS-2 has generally good inter-rater reliability across 
the nine domains with 7/9 ICCs over 0.65 and modest discriminant validity with better than chance 
discriminant validity for 7/9 domains in comparison with our subjective global ratings of pragmatism.  
The two domains which were not statistically better discriminants than chance were Flexibility 
Adherence and Recruitment, and this is likely because both were poorly described in the trial 
protocols.  
It is important to note that PRECIS-2 was developed to help designers of trials to match their design 
choices to their intended degree of pragmatism, not for retrospective assessment of trials designed 
by others and that the poor description of certain domains in the protocols is therefore not relevant 
to the main use of this tool.  Trial design teams would be much more familiar with the intricate 
details of each domain for a trial they were currently designing, than would be our assessors, who 
were rating trials they did not design. Since it was not logistically possible to work with large enough 
trial design teams, during their design process, to evaluate performance of the PRECIS-2 tool we 
constructed an artificial situation which would be expected to underestimate both inter-rater 
reliability and discriminant validity. It is encouraging that inter-rater reliability was still good, and 
discriminant validity modest, even when PRECIS-2 was used by researchers unconnected with the 
trial being scored.  
Sensitivity analysis indicated there was no obvious difference in the scores between individuals with 
regard to country, research area, or profession who completed 10 or 15 trials. The main reasons for 
not assessing all 15 trial protocols using PRECIS-2 was lack of time.  
Strengths and Limitations 
This is the first validation and estimation of reliability of the PRECIS 2 tool, which was never done for 
the original PRECIS tool [1,2]. We involved raters who reflect the target group of experienced trialists 
who could be future users of the PRECIS-2 tool. The sample of trial protocols that they assessed was 
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varied, indicating the tool can be used for diverse trial designs.   Our assumption that raters have 
limited time turned out to be correct and we were unable to get all 15 raters to complete all 15 
trials.   Also, some raters did not score particular domains giving various reasons, for instance 
Eligibility, Organisation, Flexibility (delivery) were not scored on medical and surgical trials due to 
lack of expertise in the area (e. g. physiotherapist) who reported:  “No entry, obviously no content 
knowledge on this one. Too far afield of my content to judge.” Other examples of explanations for 
missing ratings included: for Recruitment, Organisation,  “inadequate information”, for Setting 
“unclear to judge”, for Flexibility (adherence) “although mentioned in most study protocols in 
protocol publications often not enough information is given to judge on this”. Many of the imputed 
values are needed due to “lack of time” or whole trials not being scored by individual raters. 
Comparing the values for the different batches of trials and indeed for a complete set there is little 
difference in the values for the ICC thus the impact of the missing data on our assessment of 
interrater reliability was not serious.  
We are confident in the ability of PRECIS-2 to pick out trials taking different design approaches, and 
that different raters looking at the same trials come to similar conclusions. We have used the 
feedback from participants in validity and reliability testing of PRECIS-2 to add additional information 
to the guidance for users on PRECIS-2 [19] and the PRECIS-2 website http://www.precis-2.org/.  
Asking raters to retrospectively score trial protocols is perhaps a rather artificial way of using the 
PRECIS-2 tool when we suggest that it is used at the design stage by the team designing the trial. 
While a prospective study is conceivable, the time that would be needed to do it was prohibitive.  
The results presented here could be considered as a worst-case test of the tool given that there was 
sometime inadequate reporting of trial information that was relevant to assessing the PRECIS-2 
domains. This was also one of the reasons for a high percentage of missing data (in addition to the 
being unable to get a fully completed assessment of 15 trial protocols by 15 raters). This highlights a 
need to adhere to the SPIRIT statement [11] to improve reporting of information on design and 
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methods and in conjunction the CONSORT statement for pragmatic trials [15] and also the full 
CONSORT statement for randomised trials (http://www.consort-statement.org) as this data is useful 
to understand a trial’s design and assess applicability of trials.  
Discriminant validity could only be tested using a global, dichotomous ‘more pragmatic’ or ‘more 
explanatory’ assessment based on the independent judgement of ST and KL rather than on the 
judgements of more raters.  This was to reduce workload but may have an impact on the results. 
Clearly, judgements based on the opinions of more raters would have been preferable but we were 
very wary of the burden we were already placing on raters. 
Conclusion 
The validity and reliability of the PRECIS-2 tool is modest, even when tested retrospectively using 
individuals unconnected with the trials being scored. PRECIS-2 is a relatively simple, visual tool that 
can be used to focus the trial team’s discussion on the match between their design decisions and the 
needs of those for whom the results are intended, and this perhaps helps to explain why PRECIS-2 is 
already proving  useful in pragmatic trial design [16]. We believe it could also be helpful in reducing 
research waste [17] by helping trialists to consider the consequences of their design decisions on the 
usefulness of the trial results to their intended users.  
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